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RESIDUAL INJURY in tissues has always
been noted to varying extents after radio-
therapeutic treatments. This is expressed
as a slowly developing injury (e.g. fibrosis)
or as a persistently reduced function which
can be aggravated by subsequent trauma.
The importance of knowledge of the
mechanisms underlying these effects has
become more prominent in recent years
due to (a) increasing use of adjuvants to
radiation treatments, which might en-
hance existing residual damage or even
expose a latent residual injury when given
subsequently, and (b) neutron treatments
where there have been indications for
some tissues ofa difference in the relation-
ship between early and late effects. At this
symposium a group of investigators was
gathered to try to define the target cells
for residual radiation injury in many
different tissues, and to describe the state
of our knowledge of the cellular defects
responsible for this persistent injury.
SYNOPSIS
A clinical introduction was provided by
R. D. Hunter, who described some of the
residual defects in tissue function after
11
radical treatments. Recovery of tolerance,
particularly in skin, was also discussed.
Patients treated a few decades earlier for
benign conditions, with doses resulting in
telangiectasia and stigmata, could tolerate
in most cases a standard radical treatment
to an induced tumour. Tissue models were
discussed by T. E. Wheldon (with A. S.
Michalowski) to explain the times of
appearance of tissue damage and the
dependence of the time on the dose.
Tissue components could be classed as
hierarchical (H) if they were generated
from a minority of stem cells, or flexible
(F) if all cells had equal potential for
division. Type H tissues, in contrast to
type F, would be characterized by (a)
morphological heterogeneity of cells (b)
different cells for function and prolifera-
tion, and (c) an appearance of damage
equivalent to the life span of the mature
cells plus the transit time from any
resistant precursor cells, and (d) a constant
interval to appearance ofinjury at all high
doses. The dogma that vascular damage
was the root cause of all late injury was
attacked by H. R. Withers. The evidence
given included the different times of onset16TH PATERSON SYMPOSIUM
of damage among tissues, and different
doses and different relative doses of
neutrons required among tissues. Another
aspect described was that the target cells
for late effects generally show a greater
fractionation effect, and hence to minimize
late effects relative to early effects, small
dose fractions should be used.
Focusing now on specific tissues, J. H.
Hendry described the different levels of
residual injury seen in haemopoietic
tissues after repeated irradiation of mice.
Although peripheral blood counts re-
covered to near normal, the stem cells were
depleted most, to 10% of control. Extra
proliferation and amplification maintained
the tissue until the late hypoplastic phase.
The self-renewal ability of the stem
cell population was permanently reduced,
and the fibroblastic colony-forming cells
in the environment were depleted rela-
tively less by low doses per fraction but
equally by large fractions. E. Hamilton
described functional defects in colon. In
the colonic mucosa, the cryptogenic cells
had the ability to reconsitute much of the
crypt population after 6 repeated deple-
tions by 12-5 Gy at 6-week intervals.
However, there was an induced resistance
to depletion, traced to a decrease in cell
sensitivity, and this could be partially
removed using a radiosensitizer, indicating
a role for induced hypoxia.
J. R. K. Savage discussed chromosomal
lesions as a persistent cellular defect. In
a dividing population, symmetrical aber-
rations would be expected to reach an
equilibrium level, and unstable non-
symmetrical types to disappear from the
population. Studies on patients treated for
ankylosing spondylitis and cervical cancer
were reviewed, as was experimental evi-
dence using skin fibroblasts, liver, and
thyroid. The observation of persistent
asymmetrical aberrations when cells were
later stimulated into division suggested
that the initial lesions are not fixed until
the cell goes into division, and hence a
long-term repair mechanism could oper-
ate. R. H. Mole discussed radiation car-
cinogenesis, with respect to expression
times and dose-response relationships.
Results from surveys after clinical treat-
ments (e.g. forbenign and malignantpelvic
diseases) were in agreement with the
classical picture of a bell-shaped dose-
incidence curve. The induction of myeloid
leukaemia in mice showed the same
pattern. At high doses cell sterilization
would reduce the incidence.
Lung was the subject of several presen-
tations: S. B. Field described the com-
prehensive studies on the response to
fractionated doses in lung, spinal cord and
skin, including "slow repair". In general,
residual injury was greater after neutrons
and greater for late effects, when tested
using a second treatment. The notion of a
complete absence of "slow repair" in lung
after neutrons was challenged by J. F.
Fowler, as other studies on breathing rate
revealed a significant effect of prolonging
the interval between split doses. Studies
on the interaction of drugs and radiation
by G. G. Steel (with C. H. Collis and
J. Down) revealed marked variations in
effect with respect to time interval and
the drug used. Interestingly, anaesthesia
reduced early radiation damage (pneumo-
nitis) but not late damage (fibrosis). J. R.
Maisin described detailed histological
studies on the 3 temporal phases of lung
injury after doses > 20 Gy. Initially there
are focal permeability changes in many
cell types, secondly a spreading of dam-
age and accumulations of debris, and
lastly a development of fibrosis and
vascular damage. Clearly, lung is a multi-
component tissue where the population(s)
of target cells has not yet been fully
identified. Clonogenicity assays, now being
applied to many tissues, have not yet been
applied to the problem of lung damage.
Bladder injury can be assessed by func-
tional studies (urination frequency), and
this correlated in time with a proliferative
response in the epithelium (F. A. Stewart).
However, the correlation could be for-
tuitous, as additional cyclophosphamide
caused an early increase in proliferation
but not a concomitant change in bladder
function. Urination tests can also provide
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an indication of kidney injury after
bilateral irradiation (M. Williams). The
response occurs earlier and at lower doses
than after irradiation of the bladder.
Target tissues, rather than target cells,
formed the basis of the discussion of late
radiation effects in skin (J. W. Hopewell).
Pig skin is quantitatively similar to
human skin, and two waves of reaction
were separated. The first was due to
epithelial damage and inflammation lead-
ing to scar tissue (fibrosis). The second
wave was due to dermal vascular effects
leading to ischaemia and dermal necrosis.
Different penetrations of radiation from
strontium-90 and thulium-140 were used
to characterize these features further.
H. S. Reinhold described in detail vascular
effects such as histology, endothelial-cell
sensitivity, and the importance for the
tissue of the low density of endothelial
cells. Some novel ideas were described for
the possible mechanisms involved in the
development of telangiectasia. Vascular
injury is also implicated in the "tumour
bed" effect (A. C. Begg), which contributes
variously to the reduction in growth rate
ofrecurrent tumours. The injury increases
to 2-3 months for some tumours, and then
declines, suggesting a slow turnover or
repair of damaged cells.
Lastly, glandular epithelia were re-
viewed, with emphasis on target-cell
sensitivity, and the assays available,
which have been largely unexploited
except in the thyroid (J. F. Malone).
Defects such as hypothyroidism (early
incidence linear with dose, late incidence
300 per year) could be due to the slow
turnover and gradual depletion of func-
tional cells in the tissue. The apparent
resistance of parenchymal cells, as meas-
ured for example by weight increase, was
expected from the few cell divisions
induced. Also, the degree of homogeneity
of the parenchymal-cell component of
these tissues was unknown, but the tissue
was probably type F.
To conclude, the importance ofvascular
injury in long-term tissue injury remains
controversial, and this was a recurrent
theme for many of the tissues discussed.
The general understanding of long-term
tissue defects is currently in terms of
detecting the tissue components affected,
using histological techniques. The cause
ofthis, whether indirect or direct, and the
defects in the affected cells, are generally
unknown. Currently, there are few tissues
where the target cells for continued pro-
liferation (i.e. tissue replacement), can be
identified using a clonogenicity assay. In
such cases, the clonogenic cells are usually
in a minority among othermorphologically
similar cells, and hence common histo-
logical procedures using averaging pro-
cedures over the whole cell population
could be misleading unless the tissue is
known to be definitely not type H rather
than just probably type F. At this sym-
posium, only in the marrow (and to some
extent in the intestine) was the target cell
(the tissue stem cell) pinpointed and the
defect analysed in terms of the cell's
proliferative potential.
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